15:30 , Jun 8, 2018 |  BC Week In Review  |  Company News

DRC approves compassionate use of investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
21:03 , Jun 6, 2018 |  BC Extra  |  Company News

DRC approves investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
07:00 , Mar 31, 2016 |  BC Innovations  |  Product R&D

Stalking Ebola

While the spotlight has moved away from Ebola, companies and academics are still pushing to understand more about the virus and make new therapeutics, in anticipation of the next outbreak. For scientists, the legacy of...
07:00 , Mar 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ebola glycoprotein GP1; Marburg glycoprotein GP1; Niemann-Pick disease type C1 (NPC1)

Infectious disease INDICATION: Ebola virus; viral infections In vitro and mouse studies identified cross-reactive antibodies that could help treat or protect against Ebola and Marburg viral infections. NPC1 is a host factor required for viral...
07:00 , Sep 25, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Ebola Ebola glycoprotein GP1; Ebola glycoprotein GP2 Guinea pig and nonhuman primate studies suggest ZMapp could help treat Ebola virus infection. In a series...
07:00 , Sep 25, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Ebola Ebola glycoprotein GP1; Ebola glycoprotein GP2 Nonhuman primate studies suggest a prime-boost vaccination regimen using chimpanzee-derived replication-defective adenovirus 3 (ChAd3) vectors and modified...
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Ebola virus Ebola glycoprotein GP1; Ebola glycoprotein GP2 Primate studies suggest combining anti-Ebola antibodies plus interferon-a (IFNA; IFN-a) could help...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Ebola Ebola glycoprotein GP1; Ebola glycoprotein GP2 Nonhuman primate studies suggest a cocktail of three mAbs called MB-003, which targets GP1 and GP2, could...
07:00 , Jul 11, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Ebola Ebola glycoprotein GP1 Studies in primates suggest rabies (RABV)-based vaccine vectors expressing GP1 could be used to prevent Ebola infection. In macaques immunized...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Ebola Ebola glycoprotein GP1; Ebola glycoprotein GP2 Nonhuman primate studies suggest a mAb-based treatment could help improve survival after an Ebola infection. Ebola Zaire...